Philip Howdle

UK Small Cap Trader of #IBAI (formerly #IQAI) and a lifelong supporter of @AVFCOfficial. Views my own, please DYOR.

[Philip Howdle @howdlep]

#IBAI well worth a read

AGM Statement and Business Update | Company Announcement | Investegate

https://t.co/UzvTOYE99F

[Philip Howdle @howdlep]

#avfc An excellent, comprehensive article Jacob. We are very lucky to have you covering our club. Keep up the great work👍

[Jacob Tanswell @J_Tanswell]

New: Aston Villa transfer dealsheet - incomings and outgoings:

Intent on keeping Rogers, wanting Martinez to stay, adhering to a finance plan, key positions to recruit (a pacey winger), but are also dependent on who leaves.

Free to read @TheAthleticFC #AVFC

https://t.co/kqhxa2aT9G

[Philip Howdle @howdlep]

#avfc

[UEFA Europa League @EuropaLeague]

Gaizka Mendieta: Aston Villa's potent mix of attacking flexibility, defensive rigour and set-play prowess triumphed in Istanbul 👏

[Philip Howdle @howdlep]

#avfc

[UEFA Europa League @EuropaLeague]

Buendía's #UELfinal stunner has won the fan vote for the 2025/26 Goal of the Tournament! 👏

#UELGOTT | @FlixBus

[Philip Howdle @howdlep]

#avfc

[UEFA Europa League @EuropaLeague]

👕✨ The UEFA Technical Observer Group has selected its 2025/26 UEFA Europa League Team of the Season...

#UEL | @UEFA

[Philip Howdle @howdlep]

#IBAI a nice 833k premium buy at 0.625p.

Now let's see if there is a follow through, both today and in the lead up to the AGM.

[Philip Howdle @howdlep]

#IBAI

[Imaging Biometrics @ImgBiometrics]

Yesterday was Clinical Trials Day, and we want to take a moment to recognize the incredible patients and families participating in clinical research — especially those involved in the gallium maltolate Expanded Access Program for recurrent glioblastoma.
Clinical progress does not happen without patients willing to step forward during some of the most difficult moments of their lives. Every scan, every follow-up, every shared experience contributes to a better understanding of this disease and helps inform future treatment decisions for the broader glioblastoma community.
To the patients, caregivers, physicians, and advocates participating in research and Clinical Trials: thank you for advancing hope, knowledge, and progress for others facing GBM.
Your courage matters far beyond your own journey. 💙
#ClinicalTrialsDay #Glioblastoma #GBM #BrainTumorResearch #ClinicalResearch #ExpandedAccess #GlioblastomaAwareness #NeuroOncology #CancerResearch #BrainTumorCommunity

[Philip Howdle @howdlep]

#IBAI with @Heidyll increasing his Truetide holding to 28.2% both he and Truetide need their 29.35% concert party holding in IBAI to realise the huge (IBAI) gains we all expect in the short/medium term.

[Philip Howdle @howdlep]

#IBAI Excellent news, integrating Kirkstall's organ-on-a-chip technology with IBAI's MRI analysis software to address glioblastoma from research to patient care.

KIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA | Company Announcement | Investegate

https://t.co/mGygbUNQYY

[Philip Howdle @howdlep]

#IBAI Excellent news, integrating Kirkstall's organ-on-a-chip technology with IBAI's MRI analysis software to address glioblastoma from research to patient care.

KIRKSTALL AWARDED BBSRC/NC3Rs GRANT: GLIOBLASTOMA | Company Announcement | Investegate

https://t.co/mGygbUNQYY

[Philip Howdle @howdlep]

#IBAI

"The combination of Group-wide cost savings, Kirkstall's accelerating sales trajectory and the imminent launch of IB's next-generation platforms creates a clear path to profitability in 2026."

Annual Report for the Year Ended 31 December 2025

https://t.co/YdJm4aNvUD

[Philip Howdle @howdlep]

#IBAI

Annual results due on or before 30/4. Then “throughout May we explore how advanced imaging can bring greater clarity to complex cases.”

All part of growing revenues and profitability in the new financial year.

[Imaging Biometrics @ImgBiometrics]

This #GrayMay, we’re launching a focused campaign on advancing brain tumor imaging through quantitative MRI.
From leakage correction to automated Fractional Tumor Burden (FTB) maps, we’ll highlight tools designed to reduce ambiguity and support more confident clinical decision-making.
Follow along throughout May as we explore how advanced imaging can bring greater clarity to complex cases.
#PerfusionMRI #BrainTumorImaging #Neuroradiology #Oncology

[Philip Howdle @howdlep]

#IBAI

[Imaging Biometrics @ImgBiometrics]

It's time brain tumor imaging moves beyond qualitative assessment.

Standardized fractional tumor burden (FTB) maps from @ImgBiometrics, built on IB Neuro and IB Delta T1 maps, automatically deliver quantitative, reproducible, and clinically actionable insights—

Looking forward to the discussions (and tough cases) at #ASFNR VEA this October in Newport Beach.

[Philip Howdle @howdlep]

#IBAI

[Imaging Biometrics @ImgBiometrics]

Imaging interpretation turnaround times more than double over a decade https://t.co/zlLENwbsvE

MR is up 256%. CT is up 318%. Radiologists are maxed out.

@ImgBiometrics delivers fully automated quantitative maps — objective, reproducible, and available within seconds of acquisition.

As radiology faces soaring volume and shrinking workforce capacity, IB provides what the system can’t: speed, standardization, and true scalability.

If the specialty has hit its limit, the answer isn’t more hours — it’s automation that removes variability and accelerates interpretation.

[Philip Howdle @howdlep]

#IBAI

[Imaging Biometrics @ImgBiometrics]

Professor Kathleen Schmainda will present to the NCI Quantitative Imaging Network (QIN) on advanced perfusion imaging on March 30.

The presentation is titled: “Innovation to Impact: How IB [@ImgBiometrics] Brought Perfusion MRI Tools to Clinical and Trial Deployment.”

The Quantitative Imaging Network (QIN) is a major program of the National Institutes of Health (NIH/NCI) designed to accelerate the development, validation, and clinical translation of quantitative imaging tools for cancer diagnosis, treatment planning, and therapeutic response assessment.

IB is a long-standing QIN contributor.

#QIN #NIH #QuantitativeImaging #PerfusionMRI #DeltaT1 #FTBmaps #IBNeuro #BrainTumors #NeuroOncology #Radiology #Neurosurgery #ClinicalTrials #MedicalImaging

[Philip Howdle @howdlep]

#IBAI

[Imaging Biometrics @ImgBiometrics]

Exciting to see advanced imaging translated into real-world care.
At #ISMRM, Dr. Max Krucoff showcased how #FTB maps guide biopsy targeting and #DeltaT1 quantifies LITT outcomes in glioma patients.
This is the future of objective MRI.
#BrainTumor #Neurosurgery #MRI

[Philip Howdle @howdlep]

#IBAI summarise how the GaM phase I trial data could be used and estimate value?

https://t.co/eacCbT9Ucm

[Philip Howdle @howdlep]

#IBAI this is excellent news but surely this should be the subject of an RNS.

Never miss the opportunity to promote our story to a wider audience!

[Imaging Biometrics @ImgBiometrics]

Congratulations to Dr. Mona Al‑Gizawiy of the Medical College of Wisconsin on securing a new NIH R01 award—and to announce our role as a sub‑award recipient on this important project. This five‑year, $3M grant will accelerate the understanding of gallium maltolate (GaM), a promising oral therapy targeting some of the most aggressive pediatric brain cancers.

Under Dr. Al‑Gizawiy’s leadership, the pre-clinical project will advance the combination of GaM with radiation therapy, building on early evidence that GaM can enhance treatment effectiveness. IB will support this work with our FDA‑cleared quantitative MR imaging platform—including our advanced Fractional Tumor Burden (FTB) maps—which delivers standardized, highly sensitive measures of tumor response. This capability is essential for evaluating emerging therapies and represents a key differentiator in the neuro‑oncology imaging market.

“IB’s quantitative imaging gives us an early and reliable window into how tumors respond to treatment—something conventional scans simply can’t match,” said Dr. Al‑Gizawiy.

IB packages pre-clinical imaging workflows to create a unified imaging ecosystem that strengthens our position across research and clinical markets. This initiative supports long‑term growth by expanding IB’s footprint in translational research and multi‑site trials.

#PediatricBrainCancer #ChildhoodCancerResearch #PediatricOncology #BrainTumorResearch #DIPG #Glioblastoma #ATRT #HighGradeGlioma #ftbmaps

[Philip Howdle @howdlep]

#IBAI what are the benefits of yesterday's award of a new $3m NIH grant to the Medical College of Wisconsin & a sub award to IBAI, in relation 2 the likelihood of another company advancing the completed phase I GaM trial into a new phase II trial?
https://t.co/dmx8pcPKhn

[Philip Howdle @howdlep]

#IBAI

IB News March 2026

[Imaging Biometrics @ImgBiometrics]

Read our latest News and Updates Here!
https://t.co/SEfTCDsBRP

[Philip Howdle @howdlep]

#IBAI @ImgBiometrics

IB News March 2026

https://t.co/aUVI1sEqCj